FAILED
2026-08-11 18:30:05
Predicted 2.5% → Actual -11.4%
The clinical trial results of divesiran from Silence Therapeutics serve as a positive catalyst.
If the current stock price breaks through the resistance level ($12.31), take profits; if it falls below the support level ($8.91), cut losses.
The current stock price is attempting to rebound between the support and resistance levels, indicating a buying opportunity.
RSI(14) 61.4, moving averages in a positive alignment, trading volume at 0.62 times the 20-day average, recent 7-day volatility +3.5%
Comparing the forecasted return of 2.5% with the actual return of -11.4%, it is clear that the prediction was significantly off. It is necessary to analyze what was accurate and what was missed.
Through this review, we can reaffirm the importance of support and resistance levels, and to reduce the gap between predicted returns and actual results, we will analyze more data.
There are no past similar success cases.